secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001701541-26-000015
Event type: earnings
Sentiment:  neutral
Materiality: 0.45
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics Q1 2026 net loss $9.0M; cash $118.3M; GBM trial dosed first patient
--------------------------------------------------------------------------------

- Net loss of $9.0M vs net income of $56.5M in Q1 2025 (prior year included license revenue).
- Cash, cash equivalents, and investments $118.3M as of March 31, 2026; sufficient into 2H 2028.
- R&D expenses $7.0M (down from $10.5M); G&A expenses $4.3M (down from $5.0M).
- First patient dosed in Phase 2 trial of silevertinib + temozolomide for newly diagnosed EGFRvIII+ GBM.
- Oral presentation of silevertinib Phase 2 frontline NSCLC data at ASCO 2026 on May 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154126000015/0001701541-26-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154126000015/bdtx-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001701541-26-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer